Circulating sclerostin associated with vertebral bone marrow fat in older men but not women

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 12, 2014, Pages E2584-E2590

  Ma, Yu Heng Vivian ^a   Schwartz, Ann V ^a   Sigurdsson, Sigurdur ^b   Hue, Trisha F ^a   Lang, Thomas F ^a   Harris, Tamara B ^c   Rosen, Clifford J ^d   Vittinghoff, Eric ^a   Eiriksdottir, Gudny ^b   Hauksdottir, Alda M ^b   Siggeirsdottir, Kristin ^b   Sigurdsson, Gunnar ^e,f   Oskarsdottir, Diana ^b,e   Napoli, Nicola ^g   Palermo, Lisa ^a   Gudnason, Vilmundur ^b,e   Li, Xiaojuan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ICELANDIC HEART ASSOCIATION   (Iceland)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d Maine Medical Center Research Institute   (United States)

^e UNIVERSITY OF ICELAND   (Iceland)

^f LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^g UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SCLEROSTIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ABDOMINAL FAT; ADIPOGENESIS; ADIPOSE TISSUE; AGE; AGED; ARTICLE; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE MARROW; BONE MARROW FAT; CELL FUNCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FAT MASS; FEMALE; HIP; HUMAN; LEAN BODY WEIGHT; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOCYTE; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; TRABECULAR BONE; VERTEBRA; BLOOD; COHORT ANALYSIS; GENETIC MARKER; ICELAND; METABOLISM; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; SEXUAL DEVELOPMENT; VERY ELDERLY;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; AGED; AGED, 80 AND OVER; BIOMARKERS; BONE DENSITY; BONE MARROW; BONE MORPHOGENETIC PROTEINS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; ICELAND; MALE; OSTEOCYTES; OSTEOPOROSIS; SEX CHARACTERISTICS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84916630621     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4493     Document Type: Article

References (31)

1. Riggs BL, Melton LJ III, eds. Osteoporosis Etiology, Diagnosis, and Management. 2nd ed. Philadelphia: Lippincott-Raven; 1995.
2. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179-192.
3. Szulc P, Bertholon C, Borel O, Marchand F, Chapurlat R. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res. 2013;28:855-864.
4. Modder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 1;26:373-379.
5. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013;24:489-494.
6. Armamento-Villareal R, Sadler C, Napoli N, et al. Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. J Bone Miner Res. 2012;27:1215-1221.
7. Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012;97:148-154.
8. Sheng Z, Tong D, Ou Y, et al. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf). 2012;76:797-801.
9. Urano T, Shiraki M, Ouchi Y, Inoue S. Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women. J Clin Endocrinol Metab. 2012;97:E1473-E1477.
10. Arasu A, Cawthon PM, Lui LY, et al. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab. 2012;97:2027-2032.
11. Szulc P, Boutroy S, Vilayphiou N, et al. Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res. 2013;28:1760-70.
12. Thorson S, Prasad T, Sheu Y, et al. Sclerostin and bone strength in women in their 10th decade of life. J Bone Miner Res. 2013;28:2008-2016.
13. Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res. 1971;80:147-154.
14. Griffith JF, Yeung DK, Antonio GE, et al. Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology. 2005;236:945-951.
15. Griffith JF, Yeung DK, Antonio GE, et al. Vertebral marrow fat content and diffusion and perfusion indexes in women with varying bone density: MR evaluation. Radiology. 2006;241:831-838.
16. Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Eurkaryotic Gene Expression. 2009;19:109-124.
17. Schwartz AV, Sigurdsson S, Hue TF, et al. Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. J Clin Endocrinol Metab. 2013;98:2294-2300.
18. Bjornsson G, Bjornnsson O, Davidsson D. 1982 Report ABC XXIV Health Survey in the Reykjavik area: women, stages I-III, 1968-1969, 1971-1972, and 1976-1978. Participants invitation response, etc. Reykjavik, Iceland: Icelandic Heart Association.
19. Bjornsson O, Davidsson D, Olafsson H. 1979 Report ABC XVIII Health Survey in the Reykjavik area: men, stages I-III, 1967-1969, 1970-1971, and 1974-1976. Participants invitation response, etc. Reykjavik, Iceland: Icelandic Heart Association.
20. Sigurdsson G, Aspelund T, Chang M, et al. Increasing sex difference in bone strength in old age: the Age, Gene/Environment Susceptibility-Reykjavik study (AGES-REYKJAVIK). Bone. 2006;39:644-651.
21. Binkley N, Krueger D, Gangnon R, Genant HK, Drezner MK. Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures. Osteoporos Int. 2005;16:1513-1518.
22. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R. Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab. 1;96:E1159-E1162.
23. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:234-241.
24. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE, eds. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. 2nd ed. San Francisco: Springer; 1.
25. Kennell JA, MacDougald OA. Wnt signaling inhibits adipogenesis through β-catenin-dependent and -independent mechanisms. J Biol Chem. 2005;280:24004-24010.
26. Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM, Kassem M. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. J Bone Miner Res. 2007;22:1720-1731.
27. Chen J, Shi Y, Regan J, Karuppaiah K, Ornitz DM, Long F. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One. 2014;9:e85161.
28. Syed FA, Oursler MJ, Hefferanm TE, Peterson JM, Riggs BL, Khosla S. Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos Int. 2008;19:1323-1330.
29. Wend K, Wend P, Drew BG, Hevener AL, Miranda-Carboni GA, Krum SA. ERα regulates lipid metabolism in bone through ATGL and perilipin. J Cell Biochem. 2013;114:1306-1314.
30. Greendale GA, Edelstein S, Barrett-Connor E. Endogoneous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res. 1997;12:1833-1843.
31. Drake MT, Srinivasan B, Modder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 0;95:5056-5062.